Mediator release is altered in immunotherapy-treated patients: A 4-year study

被引:0
作者
Dokic, D [1 ]
Nethe, A [1 ]
KleineTebbe, J [1 ]
Kunkel, G [1 ]
Baumgarten, CR [1 ]
机构
[1] FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, DEPT CLIN IMMUNOL & ASTHMA, OPD, D-13353 BERLIN, GERMANY
关键词
immunotherapy; mediator release; specific IgG antibodies;
D O I
暂无
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
In recent years, it has been possible to demonstrate mediator release into the nasal secretion after nasal allergen challenge in patients with allergic rhinitis. Using the nasal provocation model, we determined whether the mediator release was altered in immunotherapy-treated patients. Seventeen grass-pollen-allergic patients were examined under controlled, reproducible conditions. Serial challenges with increasing doses of grass pollen produced increasing numbers of clinical symptoms and release of mediators such as kinins, TAME-esterase activity and histamine. Ten patients received a semidepot perennial grass-pollen extract for 4 years. Seven patients served as controls and did not receive immunotherapy during the observation period. Data from the group of patients receiving immunotherapy over the first year already showed a partially significant decline in the maximal mediator release after nasal allergen challenges compared to the results of pretreated challenges, whereas controls did not show any significant changes. Nasal allergen challenges after termination of 4 years' immunotherapy significantly modified the mediator release compared to pretreatment values (TAME-esterase activity P < 0.05, kinins P < 0.01, and histamine P < 0.01). Decrease of mediator release paralleled the symptom-medication scores and quantitative skin prick test. Finally, we could demonstrate a significant correlation between specific IgG increase and mediator decrease in the treated group.
引用
收藏
页码:796 / 803
页数:8
相关论文
共 45 条
[21]   Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study [J].
Rizzo, Alessandro ;
Santoni, Matteo ;
Mollica, Veronica ;
Logullo, Francesco ;
Rosellini, Matteo ;
Marchetti, Andrea ;
Faloppi, Luca ;
Battelli, Nicola ;
Massari, Francesco .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (12) :1455-1466
[22]   The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study [J].
Guven, Deniz Can ;
Acar, Ramazan ;
Yekeduz, Emre ;
Bilgetekin, Irem ;
Baytemur, Naziyet Kose ;
Erol, Cihan ;
Ceylan, Furkan ;
Sendur, Mehmet Ali ;
Demirci, Umut ;
Urun, Yuksel ;
Karadurmus, Nuri ;
Erman, Mustafa ;
Kilickap, Saadettin .
CURRENT PROBLEMS IN CANCER, 2021, 45 (06)
[23]   Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data [J].
Raphael, Jacques ;
Richard, Lucie ;
Lam, Melody ;
Blanchette, Phillip S. ;
Leighl, Natasha B. ;
Rodrigues, George ;
Trudeau, Maureen E. ;
Krzyzanowska, Monika K. .
ONCOLOGIST, 2022, 27 (08) :675-684
[24]   Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study [J].
Jesús García-Donas ;
Guillermo de Velasco ;
Rodrigo Madurga ;
Jesús Chamorro ;
Diana Rosero ;
Olatz Etxaniz ;
Jose Luis Pérez-Gracia ;
Álvaro Pinto ;
Diego Cacho ;
María Barba ;
Pablo Borrega ;
Martín Lázaro ;
Laura Rodriguez ;
Laura Villalobos ;
Lourdes García ;
Andrés Cuellar ;
María Pilar Solís-Hernández ;
Amalia González ;
Cristina Pernaut ;
Juan Francisco Rodríguez-Moreno .
Clinical and Translational Oncology, 2024, 26 :732-738
[25]   Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study [J].
Gatterbauer, Brigitte ;
Hirschmann, Dorian ;
Eberherr, Nadine ;
Untersteiner, Helena ;
Cho, Anna ;
Shaltout, Abdallah ;
Goebl, Philipp ;
Fitschek, Fabian ;
Dorfer, Christian ;
Wolfsberger, Stefan ;
Kasprian, Gregor ;
Hoeller, Christoph ;
Frischer, Josa M. .
CANCER MEDICINE, 2020, 9 (11) :4026-4036
[26]   Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study [J].
Garcia-Donas, Jesus ;
de Velasco, Guillermo ;
Madurga, Rodrigo ;
Chamorro, Jesus ;
Rosero, Diana ;
Etxaniz, Olatz ;
Perez-Gracia, Jose Luis ;
Pinto, Alvaro ;
Cacho, Diego ;
Barba, Maria ;
Borrega, Pablo ;
Lazaro, Martin ;
Rodriguez, Laura ;
Villalobos, Laura ;
Garcia, Lourdes ;
Cuellar, Andres ;
Solis-Hernandez, Maria Pilar ;
Gonzalez, Amalia ;
Pernaut, Cristina ;
Rodriguez-Moreno, Juan Francisco .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (03) :732-738
[27]   Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study [J].
Lui, Thomas Ka Luen ;
Cheung, Ka Shing ;
Leung, Wai Keung .
HEPATOLOGY INTERNATIONAL, 2022, 16 (04) :879-891
[28]   Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study [J].
Thomas Ka Luen Lui ;
Ka Shing Cheung ;
Wai Keung Leung .
Hepatology International, 2022, 16 :879-891
[29]   Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study [J].
Schadendorf, Dirk ;
Lord-Bessen, Jennifer ;
Ejzykowicz, Flavia ;
Shi, Ling ;
Yu, Peiwen ;
Srinivasan, Swetha .
EUROPEAN JOURNAL OF CANCER, 2024, 213
[30]   The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study [J].
Tanimura, Keiko ;
Yamada, Tadaaki ;
Omura, Ayaka ;
Shiotsu, Shinsuke ;
Kataoka, Nobutaka ;
Takeda, Takayuki ;
Taniguchi, Ryusuke ;
Yamada, Takahiro ;
Takeuchi, Mayumi ;
Chihara, Yusuke ;
Morimoto, Yoshie ;
Iwasaku, Masahiro ;
Kaneko, Yoshiko ;
Uchino, Junji ;
Takayama, Koichi .
FRONTIERS IN ONCOLOGY, 2021, 11